Literature DB >> 30375143

Serum uric acid as a predictor of bipolarity in individuals with a major depressive episode.

Pedro Miguel Dos Santos Oliveira1,2, Vítor Santos1,2, Manuel Coroa1,2, Joana Ribeiro1,2, Nuno Madeira1,2.   

Abstract

OBJECTIVES: There are no well-established biomarkers to predict the risk of conversion to bipolar disorder (BD) in patients with depression. Given the putative role of purinergic neurotransmission dysfunction in BD, the purpose of our study was to evaluate if higher serum uric acid (UA) levels could predict BD conversion in depressed inpatients.
METHODS: We reviewed retrospectively the records of subjects hospitalized between June 2007 and June 2010 with a diagnosis of major depressive disorder (MDD) who had undergone routine UA levels testing at admission. At an approximate 10-year follow-up we identified subjects with a subsequent diagnosis of BD. We compared UA levels between the BD-converter and non-BD converter groups, performed Receiver operating characteristic curve analysis to evaluate the prognostic accuracy of serum UA levels and calculated the clinical utility index (CUI) as a risk biomarker for conversion to BD.
RESULTS: The study included 250 subjects (55 "BD-converters" and 195 "No BD-converters"). "BD-converters" had significantly higher plasma UA levels compared to "No BD-converters" in their index hospitalization irrespective of gender (males: 403.84 ± 91.76 vs 270.81 ± 53.58 µmol/L; U = 94.5, P < 0.001 and females 302.19 ± 52.64 vs 202.69 ± 48.93 µmol/L; t = 10.75, P < 0.001). Serum UA levels showed a very good to excellent accuracy for predicting conversion to BD in inpatients with MDD (area under the curve [AUC]: 0.90; 95% CI: 0.86, 0.94) and had a good to excellent CUI- and a moderate to good CUI+ grading for discriminating BD-converter cases from non-BD converters.
CONCLUSIONS: Our study suggests that depressed patients with higher levels of serum UA are at greater risk of a subsequent manic or hypomanic episode. The purinergic system could prove a promising path for the search of biomarkers in BD.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; major depressive disorder; uric acid

Mesh:

Substances:

Year:  2018        PMID: 30375143     DOI: 10.1111/bdi.12708

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  9 in total

1.  Peripheral biomarkers to predict the diagnosis of bipolar disorder from major depressive disorder in adolescents.

Authors:  Xiaohui Wu; Zhiang Niu; Yuncheng Zhu; Yifan Shi; Hong Qiu; Wenjie Gu; Hongmei Liu; Jie Zhao; Lu Yang; Yun Wang; Tiebang Liu; Yong Xia; Yan Yang; Jun Chen; Yiru Fang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-25       Impact factor: 5.760

2.  Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder.

Authors:  Yuncheng Zhu; Haifeng Ji; Zhiang Niu; Hongmei Liu; Xiaohui Wu; Lu Yang; Zuowei Wang; Jun Chen; Yiru Fang
Journal:  Front Psychiatry       Date:  2022-06-20       Impact factor: 5.435

3.  Comparison of Serum Uric Acid in Major Depressive Disorder and Bipolar Disorder: a Retrospective Chart Review Study.

Authors:  Soomin Kim; Sang Jin Rhee; Yoojin Song; Yong Min Ahn
Journal:  J Korean Med Sci       Date:  2020-07-20       Impact factor: 2.153

4.  Lower Serum Uric Acid Is Associated With Post-Stroke Depression at Discharge.

Authors:  Guo Li; Jinfeng Miao; Wenzhe Sun; Xiaoyan Song; Yan Lan; Xin Zhao; Xiuli Qiu; Chenyan Zhang; Zhou Zhu; Suiqiang Zhu
Journal:  Front Psychiatry       Date:  2020-02-18       Impact factor: 4.157

Review 5.  Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments.

Authors:  Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes
Journal:  BMC Med       Date:  2020-10-19       Impact factor: 8.775

Review 6.  The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Authors:  Maria Carolina Bittencourt Gonçalves; Roberta Andrejew; Carolina Gubert
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

7.  Mitochondrial Alterations in Fibroblasts of Early Stage Bipolar Disorder Patients.

Authors:  Ana P Marques; Rosa Resende; Diana F Silva; Mariana Batista; Daniela Pereira; Brigite Wildenberg; Sofia Morais; António Macedo; Cláudia Pais; Joana B Melo; Nuno Madeira; Cláudia F Pereira
Journal:  Biomedicines       Date:  2021-05-07

Review 8.  Inflammatory signaling mechanisms in bipolar disorder.

Authors:  Gregory H Jones; Courtney M Vecera; Omar F Pinjari; Rodrigo Machado-Vieira
Journal:  J Biomed Sci       Date:  2021-06-11       Impact factor: 8.410

9.  Individuals with bipolar disorder have a higher level of uric acid than major depressive disorder: a case-control study.

Authors:  Zhe Lu; Yingtan Wang; Guanglei Xun
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.